ReviewFrontiers in immunology2019
Serological Diagnosis of Autoimmune Bullous Skin Diseases.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 85 citations in OpenAlex.
- Physical Activity and Risk of Autoimmune Bullous Skin Diseases: A Prospective Cohort Study.Acta dermato-venereologica · 2026Article
- Chemiluminescence Immunoassay and Enzyme-Linked Immunosorbent Assay in the Diagnosis of Pemphigoid and Pemphigus: A Comparative Study.International journal of molecular sciences · 2026Article
- Detection of Diagnostic Antibodies in Immune-Mediated Diseases: A Focus on Antigens and Technologies.Chembiochem : a European journal of chemical biology · 2026Review
- Autoimmune Diseases of the Eyelid Skin: Molecular Pathways, Clinical Manifestations, and Therapeutic Insights.International journal of molecular sciences · 2025Review
- Antibodies to Laminin β4 in Pemphigoid Diseases: Clinical-Laboratory Experience of a Single Central European Reference Centre.Antibodies (Basel, Switzerland) · 2025Article
- Juvenile pemphigus vulgaris: A narrative review.Medicine · 2025Review
- Localized genital blisters in an elderly male.JAAD case reports · 2025Article
- Autoimmune pemphigus: difficulties in diagnosis and the molecular mechanisms underlying the disease.Frontiers in immunology · 2025Review
- Introducing human 3D skin models as a new serological diagnostic tool for severe autoimmune bullous diseases.Frontiers in immunology · 2025Article
- [Skin fragility in autoimmune blistering diseases of the skin].Dermatologie (Heidelberg, Germany) · 2024Review
- Case report: A novel high-dose intravenous immunoglobulin preparation for the treatment of severe pemphigus vulgaris failing standard therapy.The Journal of dermatology · 2024Article
- The Role of Nutrition in the Pathogenesis and Treatment of Autoimmune Bullous Diseases-A Narrative Review.Nutrients · 2024Review
- Dapsone as a Current Option for the Treatment of Autoimmune Bullous Diseases with Autoimmunity to Non-Enzymes: A Retrospective Study from a Single Central European Referral Center.Medicina (Kaunas, Lithuania) · 2024Article
- Successful Treatment of Severe Pemphigus Vulgaris with Reduced Side Effects Using a Novel IVIg Preparation.Dermatology and therapy · 2024Article
- Juvenile pemphigus vulgaris: Literature review and a rare case report.Clinical case reports · 2024Article
- Genetically Regulated Gene Expression in the Brain Associated With Chronic Pain: Relationships With Clinical Traits and Potential for Drug Repurposing.Biological psychiatry · 2024Article
- Review
- Prevalence, Spectrum and Clinical Implications of Malignancies in Patients with Bullous Pemphigoid.Acta dermato-venereologica · 2023Article
- Potential contribution of anti-p200 autoantibodies to mucosal lesions in anti-p200 pemphigoid.Frontiers in immunology · 2023Review
- Diagnostic Techniques in Autoimmune Blistering Diseases.British journal of biomedical science · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune bullous dermatoses (AIBD) encompass a variety of organ-specific autoimmune diseases that manifest with cutaneous and/or mucosal blisters and erosions. They are characterized by autoantibodies targeting structural proteins of the skin, which are responsible for the intercellular contact between epidermal keratinocytes and for adhesion of the basal keratinocytes to the dermis. The autoantibodies disrupt the adhesive functions, leading to splitting and blister formation. In pemphigus diseases, blisters form intraepidermally, whereas in all other disease types they occur subepidermally. Early identification of autoimmune bullous dermatoses is crucial for both treatment and prognosis, particularly as regards tumor-associated disease entities. The diagnosis is based on clinical symptoms, histopathology, direct immunofluorescence to detect antibody/complement deposits, and the determination of circulating autoantibodies. The identification of various target antigens has paved the way for the recent development of numerous specific autoantibody tests. In particular, optimized designer antigens and multiplex test formats for indirect immunofluorescence and ELISA have enhanced and refined the laboratory analysis, enabling highly efficient serodiagnosis and follow-up. This review elaborates on the current standards in the serological diagnostics for autoimmune bullous dermatoses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.